盐酸拉贝洛尔联合硫酸镁对妊娠期高血压患者的临床作用分析  

Clinical Analysis of Labetalol Hydrochloride Combined with Magnesium Sulfate on Hypertensive Patients during Pregnancy

作　　者：杨颖莉 陈素云[1] YANG Yingli;CHEN Suyun(Department of Obstetrics,Yancheng Maternal and Child Health Care Hospital,Yancheng,Jiangsu Province,224000 China)

机构地区：[1]盐城市妇幼保健院产科,江苏盐城224000

出　　处：《中外医疗》2023年第2期111-115,共5页China & Foreign Medical Treatment

摘　　要：目的探讨盐酸拉贝洛尔、硫酸镁联合治疗方案用于妊娠期高血压中的效果。方法方便选取2016年1月—2019年12月盐城市妇幼保健院收治的120例妊娠期高血压患者为研究对象,采用随机数表法分为参照组和治疗组,各60例。两组均接受降压、利尿、解痉、改善微循环等基础治疗,参照组采用硫酸镁治疗,治疗组在对照组基础上联合盐酸拉贝洛尔治疗。比较两组患者血压水平、血液相关指标和母婴结局。结果治疗前,两组患者血压指标、血液相关指标相似,差异无统计学意义(P>0.05);治疗1个月后,两组患者血压指标、血液相关指标均发生明显变化,治疗组舒张压(87.43±4.02)mmHg以及收缩压(134.20±8.88)mmHg均低于参照组的(90.54±4.34)mmHg、(148.06±10.32)mmHg,差异有统计学意义(t=4.072、7.886,P<0.05)。治疗组血清血管内皮生长因子(40.02±2.88)ng/L、血清基质金属蛋白酶-9(92.18±7.38)ng/mL高于对照组(34.76±3.60)ng/L、(80.54±7.98)ng/mL,血小板α颗粒膜蛋白140水平(11.03±1.89)μg/L低于参照组(13.88±2.01)μg/L,差异有统计学意义(t=8.838、8.295、8.001,P<0.05)。治疗组不良母婴结局与5 min Apgar<8分总发生率(6.67%)低于参照组(20.00%),差异有统计学意义(χ^(2)=4.615,P<0.05)。结论妊娠期高血压患者接受盐酸拉贝洛尔、硫酸镁联合治疗方案可更好地控制血压、改善血液指标以及母婴结局。Objective To investigate the effect of labetalol hydrochloride combined with magnesium sulfate in the treatment of hypertension during pregnancy.Methods A total of 120 patients with pregnancy-induced hypertension ad⁃mitted to Yancheng Maternal and Child Health Hospital from January 2016 to December 2019 were convenient se⁃lected as the research objects and divided into the reference group and the treatment group by random number table method,with 60 cases in each group.Both groups received antihypertensive,diuresis,spasmolysis,improvement of mi⁃crocirculation and other basic treatment,the reference group was treated with magnesium sulfate,the treatment group was combined with on the basis of the control group labelolol hydrochloride treatment.Blood pressure levels,bloodrelated indexes and maternal and infant outcomes were compared between the two groups.Results Before treatment,blood pressure indexes and blood-related indexes were similar between the two groups,and the difference was not sta⁃tistically significant(P>0.05).After one month of treatment,the blood pressure indexes and blood-related indexes of the two groups showed significant changes,the diastolic blood pressure and systolic blood pressure of the treatment group were(87.43±4.02)mmHg and(134.20±8.88)mmHg were lower than those of the control group(90.54±4.34)mmHg and(148.06±10.32)mmHg,the difference was statistically significant(t=4.072,7.886,P<0.05).Serum vascu⁃lar endothelial growth factor(40.02±2.88)ng/L and serum matrix metalloproteinase-9(92.18±7.38)ng/mL in treat⁃ment group were higher than those in control group(34.76±3.60)ng/L and(80.54±7.98)ng/mL,and the level of plate⁃letαgranule membrane protein 140(11.03±1.89)μg/L was lower than that of the control group(13.88±2.01)μg/L,and the differences were statistically significant(t=8.838,8.295,8.001,P<0.05).The total incidence of adverse mater⁃nal and infant outcomes and 5 min Apgar<8 points in the treatment group(6.67%)was lower than that in the refer⁃ence group(20.00%

关 键 词：妊娠期高血压 盐酸拉贝洛尔 硫酸镁 血压 母婴结局 

分 类 号：R714.246[医药卫生—妇产科学]